Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound
SPRING, Texas, Jul. 8 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done in breast, lung, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of retinoic acid nuclear receptor gamma which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]